FDA approves Avsola, fourth Remicade biosimilar

The FDA has approved the fourth biosimilar to infliximab, infliximab-axxq, for all eligible indications of the biologic product.Avsola (infliximab-axxq, Amgen), a biosimilar to Remicade (infliximab, Janssen), is a tumor necrosis factor blocker intended for patients with rheumatoid arthritis, in combination with methotrexate, as well as for patients with Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.”The approval of Avsola represents an important milestone across our biosimilar and inflammation portfolios,” Murdo Gordon, executiveRead More

Share on facebook
Share on twitter
Share on linkedin